potassium phosphate, dibasic 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4206 7758-11-4

Description:

MoleculeDescription

Synonyms:

  • potassium phosphate, dibasic
  • dibasic potassium phosphate
  • dipotassium hydrogen orthophosphate
  • dipotassium hydrogen phosphate
  • Molecular weight: 174.17
  • Formula: HK2O4P
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 83.42
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 1975 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sleep disorder 212.26 19.49 101 3654 81465 63403802
Infection 122.58 19.49 104 3651 229069 63256198
Product use issue 107.59 19.49 95 3660 220425 63264842
Treatment failure 85.70 19.49 80 3675 198963 63286304
Rash 68.49 19.49 120 3635 560751 62924516
Myocardial reperfusion injury 41.63 19.49 7 3748 107 63485160
Apallic syndrome 28.76 19.49 7 3748 714 63484553
Malignant neoplasm progression 27.75 19.49 29 3726 82092 63403175
Blood phosphorus decreased 26.64 19.49 10 3745 4443 63480824
Contraindicated product administered 24.33 19.49 45 3710 217603 63267664
Cytokine release syndrome 23.38 19.49 13 3742 14301 63470966
Brain death 21.65 19.49 8 3747 3402 63481865
Disease progression 21.33 19.49 31 3724 122727 63362540
Skin lesion 20.65 19.49 16 3739 30705 63454562
Joint stiffness 20.21 19.49 18 3737 41851 63443416
Mucosal dryness 19.52 19.49 7 3748 2737 63482530

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 65.05 21.02 27 1478 21619 34933807
Drug hypersensitivity 22.23 21.02 22 1483 80507 34874919

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 43.69 17.77 27 3798 44554 79696009
Myocardial reperfusion injury 43.10 17.77 7 3818 107 79740456
Cytokine release syndrome 40.96 17.77 24 3801 35974 79704589
Blood phosphorus decreased 28.25 17.77 11 3814 6657 79733906
Apallic syndrome 28.16 17.77 7 3818 961 79739602
Brain death 19.32 17.77 8 3817 5669 79734894
Mucosal dryness 19.17 17.77 7 3818 3552 79737011

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:35225 buffer compounds

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypophosphatemia off-label use 4996001
Calcium renal calculus off-label use 427649000
Anuria contraindication 2472002 DOID:2983
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Hyperphosphatemia contraindication 20165001 DOID:0050459
Sarcoidosis contraindication 31541009 DOID:11335
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Hypercalcemia contraindication 66931009 DOID:12678
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Oliguria contraindication 83128009
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hyporeninemic hypoaldosteronism contraindication 236464008
Azotemia contraindication 445009001
Severe dehydration contraindication 450316000




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle Dehydration associated with diarrhea Indication
Cattle Early treatment of scouring Indication
Cattle Treatment following intravenous fluid therapy Indication

🐶 Veterinary products

ProductApplicantIngredients
Re-Sorb, Vytrate Zoetis Inc. 6

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) POTASSIUM PHOSPHATES CMP DEV LLC N212121 Sept. 19, 2019 RX SOLUTION INTRAVENOUS 10632150 April 19, 2039 POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018694 VUID
N0000147003 NUI
D02403 KEGG_DRUG
4018694 VANDF
C0138037 UMLSCUI
CHEBI:131527 CHEBI
CHEMBL1200459 ChEMBL_ID
DB09414 DRUGBANK_ID
24450 PUBCHEM_CID
55018 RXNORM
NOCODE MMSL
007401 NDDF
010466 NDDF
CI71S98N1Z UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.03 g INTRAVENOUS NDA 23 sections
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.03 g INTRAVENOUS NDA 23 sections
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.03 g INTRAVENOUS NDA 23 sections
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.03 g INTRAVENOUS NDA 23 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 261 mg INTRAVENOUS NDA 20 sections